WIXOM, Mich., Nov. 4, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney... [read full story]
|
RELATED
|
|
Rockwell Medical (Nasdaq:RMTI - News), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia,...
Rockwell Medical (NASDAQ:RMTI - The study evaluated the kinetics of iron transfer from SFP to apo-transferrin (apo-Tf). Results showed that all available iron present in SFP was delivered to both iron-binding sites on human...
Data Show SFP-Derived Iron Binds Rapidly to Human Transferrin With Potential to Overcome Inflammation-Induced Reticuloendothelial System (RES) Block Soluble Ferric Pyrophosphate (SFP) is a novel, investigational, continuous...
Finance, Banking & Insurance, Investing & Markets, Primary Metals, Pharmaceuticals, Ambulatory Health Care, Medicines & Remedies, Scientific Discoveries, Health Care, Biopharmaceuticals, Patients, Iron, Steel & Ferroalloy, Investing, Innovation, Corporate Earnings, Corporate Performance, Medical Research, Rockwell
